Evidence map›Paper›PMID 37460409›Full record

ArticlePediatric blood & cancer2023

Children's Oncology Group's 2023 blueprint for research: Pharmacy.

Andrew R Ostrenga, Jennifer Thackray, Ha-Mill H McLearan, Kevin M Mulieri, Elizabeth Bisaccia, Olga Militano, L Lee Dupuis, M Brooke Bernhardt, COG Pharmacy Discipline Steering Committee

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Andrew R OstrengaDepartment of Pharmacy, University of Mississippi Medical Center, Children's of Mississippi, Jackson, Mississippi, USA.
Jennifer ThackrayDepartment of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-1135-5723
Ha-Mill H McLearanDepartment of Pharmacy, University of California Davis Medical Center and Children's Hospital, Sacramento, California, USA.
Kevin M MulieriDepartment of Pharmacy, Penn State Children's Hospital, Hershey, Pennsylvania, USA.
Elizabeth BisacciaDepartment of Pharmacy, Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois, USA.
Olga MilitanoStudy Development Office, Children's Oncology Group, Monrovia, California, USA.
L Lee DupuisDepartment of Pharmacy, The Hospital for Sick Children, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-7699-1061
M Brooke BernhardtDepartment of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Texas Children's Cancer and Hematology Center, Houston, Texas, USA.
COG Pharmacy Discipline Steering CommitteeDepartment of Pharmacy, University of Mississippi Medical Center, Children's of Mississippi, Jackson, Mississippi, USA.
Advocate Children's Hospital · USBaylor College of Medicine · USChildren's Oncology Group · USMemorial Sloan Kettering Cancer Center · USPenn State Milton S. Hershey Medical Center · USUniversity of California Davis Medical Center · USUniversity of Mississippi Medical Center · USUniversity of Toronto · CA

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

Children's Oncology Group (COG) pharmacists and pharmacy technicians from more than 200 COG-member institutions comprise the COG Pharmacy Discipline. Discipline members serve an essential role in the design and execution of COG clinical trials. Core activities include study drug management, study drug access, clinical trial operations, protocol harmonization, and direct patient care. Discipline members are also actively involved in continuing education, membership engagement, and research across other COG committees/domains. Future areas of committed growth for the discipline include pharmacogenomics, pharmacokinetics, pharmacoeconomics, pharmaceutics, and implementation science.

Indexed as

PharmaciesPharmacyChildDrug EvaluationHumansMedical OncologyPharmacistsclinical pharmacyclinical trialsinvestigational pharmacypharmacy

Identifiers

PMID37460409
PMCPMC10529855
OpenAlexW4384521438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.